semaglutide and heart health cardiovascular outcomes align more closely with attained dose than achieved weight loss Heart health: Wegovy may lower

In clinical trials, burping (eructation) was reported in roughly 9% of people taking semaglutide compared with under 1% taking a placebo , with figures ranging from about 3% to 13% depending on the dose

In PIONEER 10, 63% to 73% of patients were exposed to treatment for a duration of between 52 and 56 weeks and between 21% to 25% of patients in the semaglutide treatment groups were exposed to treatment between 48 and 52 weeks

The emotional toll of her struggles reached a peak when her daughters expressed their sadness at not having family photos with their mother

The mechanism behind it The main mechanism is called telogen effluvium